GSK Pharmaceuticals reports a temporary production disruption due to a fire at one of its contract manufacturing facilities; ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

GSK PLC GSK shares rose 2.35% to £13.95 Friday, on what proved to be an all-around positive trading session for the stock ...

The drugmaking giant plans to pay $1.2billion upfront to acquire Efirmosfermin from Boston Pharmaceuticals, followed by ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

Efimosfermin, a monthly subcutaneous injection, is a phase III ready medicine expected to be launched in 2029 to treat ...

Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...